Paul M Fitzpatrick

US Patent:

7531341, May 12, 2009

Filed:

Jun 12, 2006

Appl. No.:

11/451999

Inventors:

Michel Claude Vellard - Corte Madera CA, US
Paul Andrew Fitzpatrick - Albany CA, US
Emil D. Kakkis - Novato CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345

Abstract:

The present invention is directed to phenylalanine ammonia lyase (PAL) produced by prokaryotes, wherein such prokaryotic PAL wherein the PAL variant has a greater phenylalanine-converting activity as compared to a wild-type PAL. The invention thus provides compositions of bacterial PAL and biologically active fragments, mutants, variants and analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic and industrial purposes.

US Patent:

7534595, May 19, 2009

Filed:

May 25, 2007

Appl. No.:

11/807227

Inventors:

Michel Claude Vellard - Larkspur CA, US
Paul Andrew Fitzpatrick - Albany CA, US
Emil D. Kakkis - Novato CA, US
Daniel J. Wendt - Walnut Creek CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345, 514 12

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) produced by prokaryotes, wherein such prokaryotic PAL wherein the PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention thus provides compositions of bacterial PAL and biologically active fragments, mutants, variants and analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic and industrial purposes.

US Patent:

7537923, May 26, 2009

Filed:

Apr 22, 2008

Appl. No.:

12/107736

Inventors:

Emil D. Kakkis - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
Daniel J. Wendt - Walnut Creek CA, US
Sean M. Bell - San Rafael CA, US
Augustus O. Okhamafe - Concord CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.

US Patent:

7553653, Jun 30, 2009

Filed:

Sep 19, 2005

Appl. No.:

11/230374

Inventors:

Emilio Kakkis - Novato CA, US
Daniel Oppenheimer - Castro Valley CA, US
Paul Fitzpatrick - Albany CA, US
Robert Heft - D.D.O., CA
Alejandra Gamez - San Diego CA, US
Lin Wang - San Diego CA, US
Woomi Kim - Busan, KR
Mary Straub - Malibu CA, US
Marianne Patch - San Diego CA, US
Raymond C. Stevens - La Jolla CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA
The Scripps Research Institute - La Jolla CA

International Classification:

C12N 9/88

US Classification:

435232

Abstract:

The present invention pertains to the use of the protein phenylalanine ammonia-lyase, as well as the biologically-active derivatives of the said protein for preventing or treating diseases associated with a phenylalanine imbalance in a human or animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating a phenylalanine imbalance in vivo. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting more therapeutically-effective variants of said protein as well as to the selected variants themselves.

US Patent:

7790433, Sep 7, 2010

Filed:

Apr 9, 2009

Appl. No.:

12/421557

Inventors:

Emil D. Kakkis - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
Daniel J. Wendt - Walnut Creek CA, US
Sean M. Bell - San Rafael CA, US
Augustus O. Okhamafe - Concord CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

C12N 9/88
A61K 38/00

US Classification:

435232, 530345

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.

US Patent:

20100278802, Nov 4, 2010

Filed:

Jul 9, 2010

Appl. No.:

12/833911

Inventors:

Emil D. KAKKIS - Novato CA, US
Paul A. Fitzpatrick - Albany CA, US
Daniel J. Wendt - Walnut Creek CA, US
Sean M. Bell - San Rafael CA, US
Augustus O. Okhamafe - Concord CA, US

Assignee:

BioMarin Pharmaceutical Inc. - Novato CA

International Classification:

A61K 38/51
A61P 35/00

US Classification:

424 945

Abstract:

The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.

US Patent:

20130039898, Feb 14, 2013

Filed:

Feb 3, 2011

Appl. No.:

13/576625

Inventors:

Augustus O. Okhamafe - Concord CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - Novato CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - NOVATO CA

International Classification:

A61K 38/51
A61P 3/00
A61P 7/00
C12N 9/88

US Classification:

424 945, 435232

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.

US Patent:

20190345475, Nov 14, 2019

Filed:

Jan 11, 2019

Appl. No.:

16/246300

Inventors:

- Novato CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - San Rafael CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - Novato CA

International Classification:

C12N 9/88
A61K 47/60
A61K 9/00
C07K 1/14
A61K 38/51

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.